EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieOpen Access · CC BY 4.0

Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome

Wout Willem Antoon van den Broek iD, Jaouad Azzahhafi iD, Dean R P P Chan Pin Yin iD, Niels M R van der Sangen iD, Shabiga Sivanesan, Lea M Dijksman iD, Ronald J Walhout iD, Melvyn Tjon Joe Gin iD, Nicoline J Breet, Jorina Langerveld, Georgios J Vlachojannis iD, Rutger J van Bommel iD und 5 weitere

European Heart Journal - Cardiovascular Pharmacotherapy · 2025

DOI: 10.1093/ehjcvp/pvae087 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2025. Verfasst von Wout Willem Antoon van den Broek und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Cytochrome P-450 CYP2C19, Drug Costs, Drug Substitution. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

A genotype-guided P2Y12-inhibitor de-escalation strategy, switching acute coronary syndrome (ACS) patients without a CYP2C19 loss-of-function allele from ticagrelor or prasugrel to clopidogrel, has shown to reduce bleeding risk without affecting the effectivity of therapy by increasing ischaemic risk. We estimated the cost-effectiveness of this personalized approach compared to standard dual antiplatelet therapy (DAPT; aspirin plus ticagrelor/prasugrel) in the Netherlands. Methods and results We developed a 1-year decision tree based on results of the FORCE-ACS registry, comparing a cohort of ACS patients who underwent genotyping with a cohort of ACS patients treated with standard DAPT. This was followed by a lifelong Markov model to compare lifetime costs and quality-adjusted life years (QALYs) for a fictional cohort of 1000 patients. The cost-effectiveness analysis was performed from the perspective of the Dutch healthcare system. A genotype-guided de-escalation strategy led to an increase of 57.73 QALYs and saved €808788 compared to standard DAPT based on a lifetime horizon. Probabilistic sensitivity analysis showed that the genotype-guided strategy was cost-saving in 96% and increased QALYs in 87% of simulations. The intervention remained cost-effective in the scenario where prices for all P2Y12 inhibitors were equalized. The genotype-guided strategy remained dominant in various other scenarios and sensitivity analyses.

Conclusion

A genotype-guided de-escalation strategy in patients with ACS was both cost-saving and yielded higher QALYs compared to standard DAPT, highlighting its potential for implementation in clinical practice.

Trial registration

ClinicalTrials.gov identifier: NCT03823547.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeCytochrome P-450 CYP2C19Drug CostsDrug SubstitutionDual Anti-Platelet TherapyPharmacogenomic TestingPharmacogenomic VariantsPlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsAgedFemaleHumansMaleMiddle AgedClopidogrelCost SavingsCost-Benefit AnalysisDecision TreesHemorrhageMarkov ChainsModels, EconomicNetherlandsPhenotypePrecision MedicineQuality-Adjusted Life YearsRegistriesRisk FactorsTicagrelorTime Factors

Stichwörter der Autor:innen

ACSCoronary artery diseaseCost-effectivenessGenotype-guidedP2Y12-inhibitor

Substanzen

ClopidogrelCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsTicagrelor

Autor:innen und Institutionen

  • Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
  • Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
  • Department of Value-Based Healthcare, St. Antonius Hospital, Nieuwegein, The Netherlands.
  • Department of Cardiology, Hospital Gelderse Vallei, Ede, The Netherlands.
  • Department of Cardiology, Rijnstate Hospital, Arnhem, The Netherlands.
  • Department of Cardiology, Gelre Hospitals, Apeldoorn, The Netherlands.

ORCID-Profile: Wout Willem Antoon van den Broek, Jaouad Azzahhafi, Dean R P P Chan Pin Yin, Niels M R van der Sangen, Lea M Dijksman, Ronald J Walhout, Melvyn Tjon Joe Gin, Georgios J Vlachojannis, Rutger J van Bommel, Yolande Appelman, Ron H N van Schaik, Wouter J Kikkert, Jurriën M Ten Berg

Förderung

  • ZonMw

Zitieren

APA

van den Broek, W. W. A., Azzahhafi, J., Chan Pin Yin, D. R. P. P., van der Sangen, N. M. R., Sivanesan, S., Dijksman, L. M., Walhout, R. J., Tjon Joe Gin, M., Breet, N. J., Langerveld, J., Vlachojannis, G. J., van Bommel, R. J., Appelman, Y., van Schaik, R. H. N., Henriques, J. P. S., Kikkert, W. J., & Ten Berg, J. M. (2025). Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae087

Vancouver

van den Broek WWA, Azzahhafi J, Chan Pin Yin DRPP, van der Sangen NMR, Sivanesan S, Dijksman LM, et al. Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome. European Heart Journal - Cardiovascular Pharmacotherapy. 2025. doi:10.1093/ehjcvp/pvae087

BibTeX
@article{vandenBroek2025,
  author = {van den Broek, Wout Willem Antoon and Azzahhafi, Jaouad and Chan Pin Yin, Dean R P P and van der Sangen, Niels M R and Sivanesan, Shabiga and Dijksman, Lea M and Walhout, Ronald J and Tjon Joe Gin, Melvyn and Breet, Nicoline J and Langerveld, Jorina and Vlachojannis, Georgios J and van Bommel, Rutger J and Appelman, Yolande and van Schaik, Ron H N and Henriques, José P S and Kikkert, Wouter J and Ten Berg, Jurriën M},
  title = {Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2025},
  doi = {10.1093/ehjcvp/pvae087}
}
Kostenlos starten →